SARS-CoV-2 specific T cell therapy
/ University of Cologne
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 21, 2021
ACT-COVID-19: Adoptive SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
(clinicaltrials.gov)
- P1/2; N=51; Not yet recruiting; Sponsor: Universitätsklinikum Köln
Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1